Skip to content
Life Sciences Series A Founded 2021

Circular Genomics

Circular Genomics provides RNA-based diagnostics and therapeutics for treating depression and other psychiatric and neurological conditions. The company has developed circular RNA-based genomic assays that serve as biomarkers to predict therapeutic response for individuals with psychiatric disorders, enabling personalized treatment selection. Founded in 2021 and headquartered in Albuquerque, United States, Circular…

📍 Albuquerque, United States · Genomics,

Funding snapshot

Last roundSeries A
Amount$15M
Date1 December 2025
Total raised$29M
Team size19

About

Circular Genomics provides RNA-based diagnostics and therapeutics for treating depression and other psychiatric and neurological conditions. The company has developed circular RNA-based genomic assays that serve as biomarkers to predict therapeutic response for individuals with psychiatric disorders, enabling personalized treatment selection. Founded in 2021 and headquartered in Albuquerque, United States, Circular Genomics has raised approximately $29M in Series A funding from investors including Mountain Group Partners, The University of New Mexico, Cottonwood Technology Fund, Tramway Venture Partners, and Alzheimer's Drug Discovery Foundation. The company employs 19 people and leverages circular RNA biomarkers, which are more stable than linear RNA, to develop diagnostic tests that can predict patient response to antidepressant medications, addressing the trial-and-error approach that currently characterizes psychiatric drug selection.

Business model

Neurology > In-Vitro Diagnostics > Diversified,

Genomics > Applied Genomics > Clinical Genomics > Theranostics

Institutional investors

Mountain Group Partners The University of New Mexico Cottonwood Technology Fund Tramway Venture Partners Alzheimer's Drug Discovery HIP Fund

Latest coverage

No articles yet.

Raising like Circular Genomics?

Analyze your pitch deck before your next raise.

Analyze My Deck →